Introduction
Stevens-Johnson syndrome (SJS) is a rare but serious medical emergency that is usually identified by its pattern of rapidly developing skin and mucous membrane injury, often after exposure to a medication or, less commonly, an infection. Diagnosis is primarily clinical, meaning it depends on recognizing the characteristic appearance and timing of the illness rather than on a single definitive blood test. Because the condition can progress quickly and may overlap with other severe skin disorders, accurate diagnosis is essential for stopping the triggering exposure, guiding treatment, and reducing the risk of complications such as dehydration, eye injury, infection, and widespread tissue damage.
Medical professionals diagnose SJS by combining bedside examination, careful medication review, laboratory testing, and in many cases a skin biopsy. The process is aimed not only at confirming the disorder, but also at distinguishing it from conditions that can look similar at first, including toxic epidermal necrolysis, erythema multiforme, extensive drug eruptions, and certain infections. In practice, diagnosis is a synthesis of history, physical findings, and exclusion of alternatives.
Recognizing Possible Signs of the Condition
Suspicion for Stevens-Johnson syndrome usually begins when a patient develops an acute illness with systemic symptoms followed by painful skin and mucosal changes. A common early pattern includes fever, fatigue, sore throat, cough, burning eyes, or general malaise before visible skin lesions appear. The skin findings are often more painful than itchy, which can be an important clue. Small red or purple spots may evolve into flat atypical target-like lesions, blistering, and areas of skin detachment. The hallmark is involvement of the skin together with mucous membranes such as the mouth, lips, eyes, and genital area.
Doctors are especially alert when the illness occurs within days to weeks of starting a new medication, particularly drugs known to cause severe hypersensitivity reactions. Antibiotics, anticonvulsants, allopurinol, and some anti-inflammatory medications are among the more common triggers. The timing matters because SJS is usually the result of an immune-mediated reaction in which cytotoxic T cells and related inflammatory pathways trigger keratinocyte death. That process helps explain why the skin begins to separate from the underlying layers and why symptoms can escalate rapidly once the reaction is underway.
Clinical signs that raise suspicion include widespread tender rash, erosions in the mouth, crusting of the lips, conjunctival redness, pain on swallowing, and tenderness of the skin with a positive Nikolsky sign, meaning the upper layer of skin can separate with gentle pressure. Not every patient presents with the full picture early on, so clinicians often consider SJS when a febrile patient has an unexplained rash plus mucosal involvement, especially after a new drug exposure.
Medical History and Physical Examination
The diagnostic process begins with a detailed history. Clinicians ask when symptoms started, how quickly they progressed, and whether any new prescription drugs, over-the-counter medicines, herbal products, or recent vaccines were used in the preceding one to eight weeks. They also ask about prior drug reactions, recent infections, autoimmune disease, cancer, transplant history, and immunosuppressive therapy. These details are important because the underlying trigger strongly influences both diagnosis and management.
During the history, doctors try to determine whether the eruption is painful or itchy, whether there were early constitutional symptoms, and whether the patient has difficulty eating, drinking, seeing, urinating, or opening the mouth. Eye symptoms are especially important because ocular involvement can become severe and cause long-term scarring if not recognized early. A history of recent mycoplasma infection or viral illness may also be relevant, particularly in younger patients.
The physical examination focuses on the distribution and type of skin lesions and on the extent of mucosal involvement. Physicians assess the body surface area affected by detachment or blistering, because the amount of skin loss helps determine whether the process is SJS or the more extensive toxic epidermal necrolysis. They look for dusky or targetoid lesions, erosions, blistering, crusting, and areas where the epidermis is lifting away. The exam also includes the eyes, mouth, nose, throat, and genital mucosa. Vital signs and general appearance are checked for dehydration, hypotension, tachycardia, and signs of systemic illness.
Because SJS can involve multiple organ systems, clinicians may evaluate lung symptoms, abdominal pain, urinary symptoms, and neurologic status as well. The physical examination is not simply descriptive; it helps determine severity, identify complications, and estimate whether hospitalization or intensive care is needed.
Diagnostic Tests Used for Stevens-Johnson Syndrome
There is no single laboratory value that confirms Stevens-Johnson syndrome. Testing is used to support the diagnosis, rule out other conditions, assess organ involvement, and identify complications. The most important test in many cases is a skin biopsy, but laboratory studies and sometimes imaging also contribute to the overall assessment.
Laboratory tests often include a complete blood count, electrolytes, kidney function tests, liver enzymes, and inflammatory markers. These tests do not diagnose SJS by themselves, but they help show whether the reaction has caused dehydration, acute kidney injury, electrolyte imbalance, hepatic involvement, or infection. If the patient has fever or appears ill, blood cultures may be taken to evaluate for sepsis. In selected cases, tests for infections such as Mycoplasma pneumoniae, herpes simplex virus, or other viral illnesses may be ordered when the history suggests an infectious trigger rather than a medication reaction.
Some clinicians may also use additional studies to evaluate nutritional status or fluid loss, because patients with painful oral erosions often cannot maintain normal intake. If there is concern for systemic involvement, urine studies, chest imaging, or arterial blood gas analysis may be used depending on the symptoms.
Imaging tests are not central to the diagnosis of SJS, but they can help evaluate complications or look for associated infections. A chest X-ray may be obtained if there are respiratory symptoms, fever, or concern for pneumonia. In some settings, imaging can help identify complications such as aspiration or secondary infection. Imaging is generally supportive rather than confirmatory.
Functional tests are mainly used to assess organ function affected by the illness. Eye examination by ophthalmology is one of the most important functional assessments because conjunctival inflammation, corneal injury, and eyelid involvement can lead to lasting vision problems. Visual acuity testing, slit-lamp examination, and fluorescein staining may be performed to detect ocular surface damage. Swallowing or nutritional assessments may be needed if oral lesions are extensive. Kidney and liver function tests also serve a functional role by showing whether organs are being affected by the inflammatory process or by dehydration.
Tissue examination is often the most useful confirmatory test. A skin biopsy typically shows full-thickness epidermal necrosis with sparse dermal inflammation and separation of the epidermis from the dermis. This pattern reflects the immune-mediated destruction of keratinocytes that is characteristic of SJS and toxic epidermal necrolysis. Histopathology can help distinguish SJS from other blistering disorders, though early lesions may sometimes be less specific. Direct immunofluorescence may be performed in selected cases to rule out autoimmune blistering diseases such as pemphigus vulgaris or bullous pemphigoid, which can produce overlapping findings.
Interpreting Diagnostic Results
Doctors interpret test results in the context of the clinical picture rather than in isolation. A patient with recent drug exposure, fever, painful rash, mucosal involvement, and biopsy findings of epidermal necrosis is highly likely to have SJS. Laboratory abnormalities such as elevated creatinine, low sodium, abnormal liver enzymes, or leukocytosis do not establish the diagnosis, but they suggest systemic involvement and help with severity assessment.
The extent of skin detachment is crucial for classification. If epidermal detachment involves less than 10 percent of body surface area, the diagnosis is generally Stevens-Johnson syndrome. Involvement of 10 to 30 percent is considered overlap, and more than 30 percent is classified as toxic epidermal necrolysis. This distinction matters because it reflects disease severity and affects prognosis, even though the disorders are considered part of the same clinical spectrum.
Biopsy results are interpreted alongside timing and drug history. Full-thickness epidermal necrosis strongly supports SJS, but clinicians still need to identify the likely trigger and exclude alternative explanations. If the clinical course is atypical, the rash is primarily itchy rather than painful, mucosal surfaces are spared, or the biopsy does not fit the expected pattern, the diagnosis may need to be reconsidered.
Results also help guide prognosis. Extensive skin loss, abnormal kidney or liver function, advanced age, cancer, and delayed withdrawal of the causative drug are associated with more severe disease and poorer outcomes. In practice, the diagnostic process is also a risk assessment.
Conditions That May Need to Be Distinguished
Several disorders can resemble Stevens-Johnson syndrome, especially early in the course. Toxic epidermal necrolysis is the closest related condition and is separated from SJS mainly by the amount of skin detachment. Erythema multiforme may cause target lesions, but it usually has a different pattern, is more often linked to herpes simplex infection, and typically does not produce the same degree of mucosal erosions or widespread epidermal loss.
Drug-induced morbilliform eruptions, acute generalized exanthematous pustulosis, and DRESS syndrome can also be confused with SJS. These conditions are differentiated by the type of rash, degree of skin pain, presence or absence of blistering, timing after drug exposure, and associated lab abnormalities such as eosinophilia or liver involvement. Staphylococcal scalded skin syndrome is another important mimic, especially in children, but it results from bacterial toxin effects and usually has a different histologic pattern.
Autoimmune blistering diseases, bullous pemphigoid, pemphigus vulgaris, and linear IgA bullous dermatosis may require biopsy and direct immunofluorescence to distinguish them from SJS. Infections such as disseminated herpes simplex, meningococcemia, or severe viral exanthems may also be considered depending on the clinical context. The distinguishing features often lie in the combination of timing, mucosal involvement, pain, skin detachment, biopsy findings, and medication exposure.
Factors That Influence Diagnosis
Several factors can make diagnosis easier or more difficult. Severity is one of the most important. In severe cases, the widespread skin loss and mucosal involvement are obvious, but in early or limited disease the presentation may be subtle and easy to confuse with a common drug rash. Rapid progression over hours to days is a warning sign that distinguishes SJS from many benign eruptions.
Age affects the differential diagnosis. In children and young adults, clinicians may place more emphasis on infectious triggers and conditions such as erythema multiforme, whereas in older adults drug-induced SJS is often a more likely consideration. Underlying illnesses such as HIV infection, autoimmune disease, malignancy, or recent transplant can alter both risk and presentation. Immunocompromised patients may have atypical findings or concurrent infections that complicate interpretation.
Medication history can also be difficult to interpret when patients take multiple drugs, start and stop medications intermittently, or receive over-the-counter treatments that are easily overlooked. Because SJS can occur after a delay, clinicians must review all exposures from the prior several weeks, not just medicines started in the last few days. Prior episodes of drug reactions increase suspicion when a similar medication is involved again.
Access to specialists influences diagnosis as well. Dermatology consultation and ophthalmology evaluation can improve diagnostic accuracy, especially when biopsy or eye involvement needs rapid assessment. In hospitalized patients, the diagnosis may be made more quickly because of closer monitoring and the ability to perform targeted tests promptly.
Conclusion
Stevens-Johnson syndrome is diagnosed through a careful combination of clinical observation, medication and illness history, physical examination, and targeted testing. The condition is suspected when a patient develops a painful, rapidly evolving rash with mucosal involvement, particularly after exposure to a high-risk medication. Laboratory studies help assess organ function and complications, imaging may be used when needed to evaluate associated illness, and skin biopsy can provide histologic confirmation by showing full-thickness epidermal necrosis.
Doctors confirm SJS by integrating all of this information and distinguishing it from other blistering, drug-related, infectious, and autoimmune disorders. Because the disease can progress quickly and can be life-threatening, prompt recognition and diagnostic evaluation are essential. Accurate diagnosis allows the triggering agent to be stopped, complications to be treated early, and the extent of skin and organ involvement to be assessed with as much precision as possible.